Back to top

Analyst Blog

Protalix BioTherapeutics, Inc. (PLX - Snapshot Report) recently announced the treatment of the first patient in a phase I study of PRX-112 or oral glucocerebrosidase enzyme (GCD). Oral GCD is being developed for the treatment of Gaucher disease. The phase I study is expected to end in the third quarter of 2013.

We note that Protalix already has an approved Gaucher disease product in its portfolio. Elelyso, an enzyme replacement therapy (ERT), gained approval in the US in May 2012 for the long-term treatment of adults with a confirmed diagnosis of type 1 Gaucher disease.

The product is approved in other countries as well including Israel, Brazil and Uruguay. However, as far as EU approval is concerned, the European Commission refused marketing authorization for Elelyso in Nov 2012.

In addition to its Gaucher disease candidate, Protalix is also developing PRX-102 for the treatment of Fabry disease. In Dec 2012, the company announced the treatment of the first patient in a phase I/II clinical study of Fabry patients with PRX-102.

In early 2012, the European Medicines Agency (EMA)'s Committee for Medicinal Products for Human Use (CHMP) had expressed its inability to recommend marketing authorization for Elelyso because of the presence of Shire plc’s (SHPG - Analyst Report) Vpriv (velaglucerase alfa) in the market. We remind investors that Vpriv received orphan drug status in the EU and has 10 years of marketing exclusivity for Gaucher disease since Aug 2010.

We note that companies like Sanofi (SNY - Analyst Report) have a presence in the Gaucher disease market.

Currently Protalix carries a Zacks Rank #3 (Hold). Comparatively companies like Cytokinetics, Inc. (CYTK - Snapshot Report) look better positioned, carrying a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%